Vitiligo
Pipeline by Development Stage
Drug Modality Breakdown
Vitiligo is a $4.0B dermatology market dominated by JAK inhibitors, currently in a mature consolidation phase with major patent cliffs approaching.
Key Trends
- JAK inhibitors command 75% of market spend; topical formulations (OPZELURA) emerging as key growth vector
- Patent cliff risk: $1.9B JAKAFI revenue exposed by 2028; significant generic conversion anticipated
- Pipeline activity concentrated in Phase 2-3; limited breakthrough mechanisms beyond JAK inhibition
Career Verdict
Solid specialty choice for commercial and medical affairs professionals, but R&D careers face limited innovation upside; recommend entry focus on market transition strategies post-LOE.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OPZELURA (Ruxolitinib) | Incyte | $76M | 2% | Peak | Growing | 15.0yr |
| 2 | ZORYVE (Roflumilast) | Arcutis Biotherapeutics | $7M | 0.2% | Growth | Growing | 16.3yr |
| 3 | EUCRISA (Crisaborole) | R-Pharm US | $10M | 0.3% | Peak | Stable | 4.2yr |
Drug Class Breakdown
dominant but facing generic erosion post-2026
emerging topical opportunity
includes off-label JAK use
niche positioning
minimal penetration
Career Outlook
StableVitiligo is a stable, cash-generative market ideal for commercial and medical affairs professionals seeking secure mid-career positions with strong compensation. However, R&D specialists should approach cautiously due to limited pipeline innovation and upcoming patent cliffs that will trigger restructuring waves starting 2026. Best entry point is Commercial or Medical Affairs roles at large pharma (AbbVie, AstraZeneca, Pfizer) where job volume and salary support career progression.
Breaking In
Join a large pharma commercial team (AbbVie, AstraZeneca, Pfizer) in a Brand Manager or MSL role to build dermatology expertise and benefit from current market momentum before 2026 patent cliffs.
For Experienced Professionals
Experienced professionals should target Medical Affairs or Market Access leadership roles now; avoid early-career R&D positions given limited pipeline and plan exit or redeployment strategies by 2025.
In-Demand Skills
Best For
Hiring Landscape
Total vitiligo-specific hiring stands at 4,234 jobs, with dominant positions at large pharma (AbbVie, AstraZeneca, Sanofi). Commercial roles lead hiring (592 jobs, $246K avg), followed by manufacturing (569 jobs) and R&D (431 jobs). Hiring heavily skewed toward Commercial and Medical Affairs, reflecting mature market focus on execution over innovation.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and job stability; Manufacturing and R&D roles face post-LOE headcount risk starting 2026.
On Market (3)
Approved therapies currently available
Competitive Landscape
17 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 29 trials with date data
Clinical Trials (29)
Total enrollment: 113,674 patients across 29 trials
Secukinumab in Active Non-segmental Vitiligo
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Efficacy and Safety of ACH24 in the Treatment of Vitiligo
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo
A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Mental Health Associations With Vitiligo
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Related Jobs in Dermatology
Specialty Sales Representative (Indianapolis, IN)
Territory Manager - Bakersfield
Process Expert (m/f/d) - Schaftenau, Tirol
Territory Manager - Chicago South
Specialty Sales Representative (Birmingham, AL - West)
District Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.